OncoMatch/Clinical Trials/NCT06271837
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Is NCT06271837 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Trastuzumab deruxtecan and Bevacizumab for advanced solid tumors (excluding gastric cancer and breast cancer).
Treatment: Trastuzumab deruxtecan · Bevacizumab — This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Gastric Cancer
Tumor Agnostic
Biomarker criteria
Required: HER2 (ERBB2) expression
HER2 expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate organ function and bone marrow within 14 days before enrollment
Kidney function
Adequate organ function and bone marrow within 14 days before enrollment
Liver function
Adequate organ function and bone marrow within 14 days before enrollment
Cardiac function
Protocol-defined inadequate cardiac function [excluded]
Adequate organ function and bone marrow within 14 days before enrollment. Protocol-defined inadequate cardiac function [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify